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a b s t r a c t
Recombinant cyclopentadecanonemonooxygenase fromPseudomonas sp. catalyzed thepreparative-scale
Baeyer–Villiger oxidation of numerous 3 and 17-ketosteroids with a full control of the regiochemistry of
the produced lactones. The recovered product yields were up to 42%.
© 2008 Elsevier B.V. All rights reserved.
1. Introduction
TheBaeyer–Villiger (BV) reaction is among themostwell-known
and commonly applied reactions in organic synthesis. Its versa-
tility is well established inasmuch (i) different types of carbonyl
compounds such as aldehydes, ketones and cyclic ketones can
be oxidized, (ii) the presence of other functional groups is well
tolerated and (iii) the regiochemistry is usually predictable [1].
Commonly, the reaction is performed with expensive and/or haz-
ardous peracids and a large amount of waste is produced. In order
to run this reaction with “greener” procedures, new developments
have been established using aqueous hydrogen peroxide or oxygen
and catalysts [1]. On the other hand, the oxidation of unsaturated
ketonesmay lead to a variety of products such as enol esters, epoxy
esters, and epoxy ketones and the presence of two (or more) non-
equivalent keto groups in the molecule makes the process even
more challenging [2].
The biological BV reaction is an important type of biocon-
version, utilized for numerous interesting synthetic applications
because of its high regio and/or stereoselectivity [3]. The pos-
sibility to profitably use the enzymatic BV reaction also on
diketones derivatives has been recently reported: the recombinant
cyclohexanone monooxygenase (CHMO) from Acinetobacter cal-
∗ Corresponding author. Fax: +39 02 2890 1239.
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coaceticus, selectively oxidized racemic bicyclic diketones such as
the Wieland–Miescher and the Hajios–Parrish diketones and their
derivatives [4]. CHMO belongs to the Baeyer–Villiger monooxyge-
nases (BVMOs), a versatile group of enzymes able to catalyze awide
variety of oxidative reactions [3]. BVMOs are NADPH-dependent
flavoenzymes that use atmospheric oxygen as “green and free”
oxidant. These enzymes have been employed in purified form or
directly as whole-cells; in the former case an ancillary enzymatic
reaction is required for the regeneration of the nicotinamide cofac-
tor.
Steroids represent an important class of natural products with a
multitude of pharmacological properties. It is also recognized that
minor changes in the structure of steroids can highly affect their
biological activity, which has promoted countless studies on the
modification of naturally occurring steroids in search of new and
more active compounds. The catabolism of steroids is a viable way
of producing new bioactive compounds and many examples based
on the degradation (also by BV reaction) of steroidal A [5], B [6], and
D rings [7] or of the side chain have been reported [7d–i,8]. In the
majority of the cases, these modifications have been obtained by
microorganisms with only few examples of isolated enzymes such
as cytochrome P450 or BVMOs [6,8a].
So far the two reported BVMOs, they were isolated (and
characterized) either from Cylindrocarpon radicicola [8b] or from
Rhodococcus rhodochrous [8a,9]; only the latter was sequenced and
produced as a recombinant protein in Escherichia coli (SMO). Fur-
thermore, the biocatalytic properties of the two enzymes, studied
1381-1177/$ – see front matter © 2008 Elsevier B.V. All rights reserved.
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with a small set of steroids demonstrated that they were able to
oxidize 17- and 20-ketosteroids.
Recently, a new BVMO from Pseudomonas sp. strain HI-
70, namely cyclopentadecanone monooxygenase (CPDMO), was
cloned, sequenced and overexpressed in E. coli [10]. The amino acid
sequence is quite different from those of CHMO and SMO, with
whom it shows an identity of 31 and 33%, respectively.
Apreliminary characterizationof this biocatalyst has shown that
the enzyme prefers cyclic and bicyclic ketones with 7–16 carbons
atoms [10]. To further explore the substrate-activity space that char-
acterizes CPDMO, we herein report on our studies carried out with
structurally demanding substrates such as steroids.
2. Results and discussion
2.1. D-ring oxidation
The enzymatic BV oxidation of a set of 17-ketosteroids
(1–13; Table 1) to the corresponding lactones was conducted
with a purified preparation of recombinant mutant S216A of
CPDMO from E. coli BL21(DE3) (pCpdB), which showed an
apparent increase in affinity towards NADPH as indicated by
a threefold-lower Km than that of the wild-type protein [10].
To in situ regenerate the NADPH consumed by the BV reaction,
the ancillary enzymatic system glucose-6-phosphate/glucose-
Table 1
Range of steroids studied as possible substrates for Baeyer–Villiger oxidation catalyzed CPDMOa .
aFor reaction details see Section 1.
bIsolated yield of product.
cWhole-cells.
dNo reaction.
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Scheme 1. General procedure for the enzymatic oxidation of steroids with in situ
NADPH regeneration.
6-phosphate dehydrogenase (G6PDH) [11] was employed
(Scheme 1).
Oxidation of androsterone (1) gave the 17a-oxa-17a-homo 17-
one lactone (1a) in 9% yield. This is the lactone expected upon
migration of the more substituted center, with retention of config-
uration [12]. Oxygen insertion at the C13–C17 carbon–carbon bond
of 1 was inferred by NMR analysis, which revealed the absence
the –OCH2– group (which rules out oxygen insertion at C16–C17
carbon–carbonbond), andshowed thepresence in the 13Cspectrum
of a quaternary carbon linked to an oxygen atom. This type of oxy-
gen insertion is in agreementwith previous studies on chemical BV
oxidation of 1 [13]. Inverting the stereochemistry of the 3-hydroxy
group from  to  (2) did not affect the performance of the cat-
alyst and lactone 2a was obtained in 10% yield; instead, changing
from the 5 to the 5 series as in 3, the isolated yield of the lactone
increased considerably (3a, 20% yield). A further increase in yield
was obtained for steroid 4, which has a double bond in position
5 (4a, 28% yield). The oxidation was also carried out using whole-
cells,witha42%yield for4a. Thesedata suggest thatCPDMOactivity
is quite insensitive to the stereochemistry of the 3-hydroxy group
but is affected by the stereochemistry at position 5. It should be
mentioned that steroids of the 5 series are in the trans-trans-trans
conformation, while those of the 5 series are in the cis-trans-trans
conformation,whichgives thema“bent” structure. Replacing the3-
hydroxygroupwith the acetyl ester, as in5, causes a strongdecrease
in the recovered yield of product 5a, which was only 3%. A further
increase of the bulkiness of the molecule with the pivoyl ester (6),
completely suppressed enzymatic activity.
With androstenedione 7, two keto groups are present in the
molecule, but only the 17a-oxa-17a-homo 17-one lactone 7a was
obtained (7% yield). The formation of other compounds with a dif-
ferent structure was ruled out because of the lack of any NMR
signal for –OCH2– or –OCHC– fragments. Oxygen insertion is in
agreement with our previous studies onWieland–Miescher ketone
which have shown that another BVMO, i.e. CHMO, was not able to
oxidize ,-unsaturated ketones [4]. This lactone 7a is a precursor
of testolactone that is an aromatase inhibitor and anticancer drug
[14]. Steroid8was easily transformedbyCPDMO in the correspond-
ing lactone 8a (20% yield), while the BV oxidation with peracids
of this 19-hydroxy steroid takes place through complex rearrange-
ments in the A-ring [15]. CPDMOwas unable to transform the three
estrogens 9, 10 and 11, probably due to their very low solubility in
aqueous buffer. Instead, estrogen 12, bearing a 16-hydroxy group,
gave the usual lactone 12a in 20% yield. Steroid 13 was synthesized
as a mixture of  and  epoxide [16] and, when subjected to enzy-
matic BV oxidation, yielded only trace amounts of products, which
prevented their complete characterization. The ESI mass spectrum
revealed ions atm/z319 [M+H]+ and341 [M+Na]+,which is in agree-
ment with the insertion of an oxygen atom in 13. NMR spectra
were rather complex since the starting steroid 13 was a mixture
(7:3) of diastereoisomers because of the presence of  and  epox-
ide groups (which, in turn, can produce one or more isomers). The
major isomer in the resultingmixture showed a singlet at 3.08ppm
in the proton spectrum, ascribed to the hydrogen in position 4, and
the occurrence of a quaternary carbon at 82.7ppm in the carbon
spectrum, which is characteristic of the oxidized D-ring. These low
conversions are depending on the low solubility of steroids in the
reaction buffer and the little stability of the enzymes during the
reaction.
2.2. A-ring oxidation
The regiochemistry of the 3-keto-5 and 5 steroid lactoniza-
tion ismarkedly influenced by the stereochemistry at C5 and by the
nature of the peracids used, e.g. m-chloroperbenzoic or trifluorop-
eracetic acid (Scheme2) [17]. For the3-keto-5 steroids studied, the
only products obtained, with both peracids, were the 3-oxa 4-one-
4a-homo steroids; this peculiar regioselectivitywas explainedwith
the preferential attack of the peracid, with a chair conformation of
the Criegee intermediate, to the less hindered -face [17]. For 3-
keto-5 steroids, two regioisomers with different ratios depending
on the nature of the oxidant, were obtained [17].
Table 1 depicts the structures of the 3-ketosteroids studied by
us (14–17). With androstanolone (14) the enzymatic BV reaction
gave the 3-one-4-oxa-4a-homo lactone 14a as the only regioiso-
mer (24% yield). The same was true for 15, which is similar to 14
but possesses 5 configuration, where lactone 15a was obtained in
14% yield. The occurrence and the regiochemistry of the –OCH2–
group in products 14a and 15a were inferred from NMR spectra.
13C spectra showed the oxymethylene signal at ca. 70ppm for both
compounds. In proton spectra, the signals of the –OCH2–hydrogens
felt in the3.5–4.6ppmregionandwere coupledwith a single vicinal
proton. Such spin system is consistent only with the 3-one-4-oxa-
4a-homo structure. These are the first examples of enzymatic BV
oxidation with BVMOs at the A-ring of steroids.
More intriguing is16,where twoketo groups inposition3 and17
are present and, therefore, fourmono-lactones and four di-lactones
could be envisaged. The main product obtained 16a (30% yield)
was the 3-one-4-oxa-4a-homo lactone; another product 16b (11%
yield) was identified as the di-oxidized lactone 4,17a-dioxa-4a,17a-
dihomo 5-androstan 3,17-dione. This finding indicates that 16 is
oxidized at the A-ring faster than at the D-ring, since the 17a-oxa-
17a-homo 5-androstan 3,17-dione was not detected: therefore
CPDMO seems to prefer 3-keto to 17-ketosteroids. Furthermore,
the enzymatic BV reaction seems to be independent of the stereo-
chemistry at C5, since the oxidation was fully regiospecific for both
3-keto-5- and 5-steroid to give the 3-one-4-oxa-4a-homo lac-
tones. Testosterone (17) was not a substrate for CPDMO, confirming
once more that this enzyme is not able to oxidize ,-unsaturated
ketones.
2.3. B- and C-rings and exocyclic C20 keto groups
To check the feasibility of enzymatic oxidation at B- and C-rings,
cholic acids 18–20, which have keto groups in position 7 (B-ring)
and/or 12 (C-ring), were assayed. None of these steroids was oxi-
dized by CPDMO, included the triketo derivative 21, which has also
a keto group in position 3, and the 5-cholanoic acid 22, which has
the only keto group in position 6. This behavior is probably due to
Scheme 2. Lactones expected by a BV oxidation of 3-keto-steroids.
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the presence of the side chain, that prevents the access or the cor-
rect placement of the substrate inside the enzyme active side. The
enzymatic BVoxidationof the exocyclic ketoneof pregnene steroids
was attempted with various substrates (23–32), but without suc-
cess; this supports the hypothesis that the keto group in position
20 is not accepted by the enzyme. Similarly, the keto group present
in the C-ring in position 11 of 30–33 was not accepted by CPDMO.
3. Conclusions
The exploration of the substrate-activity space of CPDMO was
conducted with 33 ketosteroids. The study showed that CPDMO in
not only able to direct and accommodate in the active site flexi-
ble rings such as cyclopentadecanone, but also more structurally
demanding compounds such as steroids. The enzyme was able to
catalyze the BV oxidation of 3-keto and 17-ketosteroids with full
control of the regiochemistry of the produced lactones. The enzy-
matic oxidations were carried out under non-optimized conditions
and, in order to have information on the relative reactivities of
the various steroids, low amounts of catalyst were employed. Sub-
stantial improvements in conversion and yield are expected by
optimization of reaction conditions and by increasing the amount
of catalyst used. Theproducts obtainedwiden the repertory of func-
tionalized compounds of potential interest in the area of medicinal
chemistry. The chance that BVMOs can take part in the catabolism
of steroidal hormones may be envisaged.
4. Experimental
General: Recombinant CPDMO was overexpressed and puri-
fied according to previously described methods [10]. Oxidation
reactions were conducted using the purified enzyme. One unit
of CPDMO oxidizes 1.0mol of 1-decalone per minute at pH 9
and 25 ◦C in the presence of NADPH. Glucose-6-phosphate dehy-
drogenase from Leuconostoc mesenteroides was obtained from
Fluka-BioChemika. Glucose-6-phosphate and NADPH were pur-
chased from Sigma–Aldrich. Fermentations were carried out with
the Labfors Infors fermenter. Flash chromatography: silica gel 60
(70–230mesh, Merck). Melting points (uncorrected) were deter-
mined with a Reichert–Kofler apparatus. IR spectra were recorded
on a Jasco FTIR 610. NMR spectra were recorded either on a Bruker
ARX 400 or a Bruker Avance 500 spectrometer, operating at proton
resonance frequencies of 400 and 500MHz (100 and 125MHz for
13C NMR, respectively) using CDCl3 as solvent and TMS as internal
reference. Partial signal assignment,wherenecessary,was achieved
performing proton–proton homocorrelation experiments (COSY)
for the hydrogen spectra and DEPT or proton–carbon heterocor-
relation experiments for the carbon spectra.
The ESI-MS spectra were recorded on a Bruker Esquire 3000+
instrument with an electrospray source and a quadrupole ion trap
detector. The samples were dissolved in CH3OH, addedwith a trace
of a solution of H2O containing 1% formic acid and infused into the
ESI source via a microsyringe pump at a rate of 4L/min.
All other compounds and steroidswere purchased fromAldrich-
Fluka-Sigma and Steraloids.
4.1. Typical procedure for steroid oxidation with isolated enzymes
Substrates (1: 50; 2: 50; 3: 25; 4: 25; 5: 140; 6: 25; 7: 60; 8: 25;
9: 90; 10: 100; 11: 25; 12: 25; 13: 35; 14: 100; 15: 25; 16: 77; 17–33:
25mg) were dissolved in a Tris/HCl buffer (50mM, pH 9.0, 10mL),
containing glucose-6-phosphate (1.5 equiv.), glucose-6-phosphate
dehydrogenase (0.6units/mgsteroid), NADP (0.08mg/mgsteroid) and
0.1units/mgsteroid of CPDMO. The mixture was shaken at 250 rpm
and 25 ◦C in a rotatory shaker for 1 day. The reactions were then
stopped, worked up by extraction with CHCl3 (3× 5mL), dried
over Na2SO4, filtered and evaporated under reduced pressure. The
residues were purified by flash chromatography on silica gel with
petroleum ether/ethyl acetate to afford the corresponding lac-
tones.
4.2. Steroid oxidation with whole-cells
Fresh LBamp medium (1 l) was inoculated with 0.2% (2ml) of
an 8h preculture of E. coli BL21(DE3) (pCpdB) in a fermenter.
The culture was incubated at 450 rpm at 30 ◦C overnight, and
then IPTG was added to a final concentration of 1mM. Steroid
4 (100mg) was added along with -cyclodextrin (0.5 equiv.) and
incubated overnight, then the biomass was separated by centrifu-
gation (20min, 5000 rpm). The supernatant was filtered through
a bed of Celite, which was subsequently washed with extraction
solvent. The aqueous layer was extracted with CHCl3 (4× 200ml)
and the combined organic layers were dried over Na2SO4, fil-
tered and evaporated under reduced pressure. The residues were
purified by flash chromatography on silica gel with petroleum
ether/ethyl acetate to afford the corresponding lactone 4a (yield
49%).
4.2.1. 3˛-Hydroxy 17a-oxa-17a-homo 5˛-androstan 17-one (1a)
Yield 9%. White powder; m.p. 233 ◦C; IR (nujol) 1715 cm−1; ESI-
MS m/z 307 [M+H]+, 329 [M+Na]+; 1H NMR: ı=4.05 (1H, quint.,
J=2.8Hz), 2.66 (1H, ddd, J=19.1, 8.8, 2.6Hz), 2.55 (1H, ddd, J=19.1,
9.5, 8.5Hz), 2.00–1.93 (2H,m), 1.86 (1H,dtd, J=12.7, 6.6, 2.7Hz), 1.80
(1H, dq, J=13.6, 3.7Hz), 1.70–1.35 (11H, m), 1.31 (3H, d, J=0.9Hz),
1.30–1.11 (4H, m), 1.02–0.94 (2H, m), 0.76 (3H, d, J=0.7Hz); 13C
NMR: ı=171.57, 83.44, 66.31, 53.15, 46.41, 39.38, 38.53, 37.96, 36.12,
35.62, 31.99, 30.57, 28.97, 28.72, 28.17, 21.63, 20.16, 19.81, 11.06.
4.2.2. 3ˇ-Hydroxy 17a-oxa-17a-homo 5˛-androstan 17-one (2a)
Yield 10%. White powder; m.p. 145 ◦C; IR (nujol) 1714 cm−1;
ESI-MS: m/z 307 [M+H]+, 329 [M+Na]+; 1H NMR: ı=3.61 (1H, tt,
J=11.1, 4.8Hz), 2.66 (1H, ddd, J=19.0, 8.5, 2.6Hz), 2.55 (1H, ddd,
J=19.0, 9.4, 8.2Hz), 2.00–1.71 (6H, m), 1.65–1.31 (9H, m), 1.30 (3H,
d, J=0.7Hz), 1.27–1.09 (4H,m), 1.04–0.82 (2H,m), 0.789 (3H, s); 13C
NMR: ı=171.47, 83.34, 71.10, 53.19, 46.40, 44.29, 39.38, 37.99, 37.89,
36.84, 35.54, 31.39, 30.66, 28.69, 28.33, 22.07, 20.13, 19.87, 12.17.
4.2.3. 3˛-Hydroxy 17a-oxa-17a-homo 5ˇ-androstan 17-one (3a)
Yield 20%.White powder;m.p. 175 ◦C; IR (nujol) 1715 cm−1; ESI-
MS: m/z 307 [M+H]+, 329 [M+Na]+; 1HNMR: ı=3.65 (1H, tt, J=11.1,
4.6Hz), 2.69–2.52 (2H, m), 2.00–1.79 (4H, m), 1.75–1.31 (13H, m),
1.29 (3H, s), 1.26–1.09 (3H, m), 1.03 (1H, td, J=14.2, 3.5Hz), 0.89
(3H, s); 13C NMR ı=171.35, 83.32, 71.58, 46.45, 41.57, 39.74, 39.53,
38.38, 36.26, 35.09, 34.78, 30.62, 28.73, 26.95, 25.21, 23.14, 21.83,
20.13, 19.95.
4.2.4. 3ˇ-Hydroxy 17a-oxa-17a-homo-androst-5-ene-17-one
(4a)
Yield 28% or 42%. White powder; m.p. 210 ◦C; IR (nujol)
1683 cm−1; ESI-MS: m/z 305 [M+H]+, 327 [M+Na]+; 1H NMR:
ı=5.36 (1H, dt, J=5.4, 2.0Hz), 3.54 (1H, tt, J=11.5, 4.4Hz), 2.69 (1H,
ddd, J=18.9, 8.5, 2.2Hz), 2.58 (dt, J=18.9, 9.0Hz), 2.34 (1H, ddd,
J=13.0, 4.8, 2.4), 2.26–2.15 (2H, m), 2.00–1.78 (5H, m), 1.71–1.35
(8H, m), 1.33 (3H, s), 1.19–1.09 (2H, m), 0.99 (3H, s); 13C NMR:
ı=171.37, 140.73, 120.57, 83.11, 71.50, 49.06, 46.79, 41.94, 38.97,
36.96, 36.63, 34.51, 31.52, 31.11, 28.83, 21.99, 20.07, 19.95, 19.30.
4.2.5. 3˛-Acetoxy 17a-oxa-17a-homo 5ˇ-androstan 17-one (5a)
Yield 3%. White powder; m.p. 150 ◦C; IR (nujol) 1731 cm−1; ESI-
MS: m/z 349 [M+H]+, 371 [M+Na]+; 1H NMR: ı=5.02 (1H, quint.,
J=2.6Hz), 2.67 (1H, ddd, J=18.9, 8.5, 2.4Hz), 2.56 (1H, ddd, J=18.9,
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9.3, 8.0Hz), 2.12–2.06 (1H, m), 2.05 (3H, s), 2.02–1.93 (3H, m), 1.87
(1H, dtd, J=12.8, 3.8, 2.6Hz), 1.82–1.73 (2H, m), 1.67–1.38 (7H, m),
1.30 (3H, d, J=0.8Hz), 1.25–1.11 (4H,m), 1.02–0.93 (2H,m), 0.77 (3H,
s); 13C NMR: ı=171.53, 170.62, 83.38, 73.38, 53.04, 46.44, 39.48,
39.37, 37.93, 35.83, 32.70, 32.65, 30.50, 28.69, 27.99, 26.02, 21.64,
21.52, 20.14, 19.82, 11.20.
4.2.6. 17a-Oxa-17a-homo-androst-4-ene 3,17-dione (7a)
Yield 7%.White powder;m.p. 195 ◦C; IR (nujol) 1716, 1666 cm−1;
ESI-MS: m/z 303 [M+H]+, 325 [M+Na]+; 1H NMR: ı=5.76 (1H, dt,
J=1.8, 0.8Hz), 2.70 (1H, ddd, J=18.9, 8.8, 2.4Hz), 2.58 (1H, ddd,
J=18.9, 9.3, 8.4Hz), 2.46–2.31 (4H, m), 2.08–1.98 (5H, m), 1.81 (1H,
dq, J=13.7, 3.6Hz), 1.74 (1H, td, J=13.7, 5.6Hz), 1.67 (1H, tdd, J=12.8,
4.2, 0.9Hz), 1.61–1.39 (3H, m), 1.36 (3H, d, J=0.9Hz), 1.35–1.29 (1H,
m), 1.17 (3H, d, J=0.7Hz), 1.17–1.06 (1H, m); 13C NMR: ı=198.90,
170.98, 169.04, 124.18, 82.63, 52.58, 45.80, 39.05, 38.47, 38.06,
35.58, 33.83, 32.35, 30.48, 28.56, 21.88, 20.06, 19.94, 17.43.
4.2.7. 19-Hydroxy 17a-oxa-homo-androst-4ene 3,17-dione (8a)
Yield 20%. White powder; m.p. 230 ◦C; IR (nujol) 1700,
1656 cm−1; ESI-MS: m/z 319 [M+H]+, 341 [M+Na]+; 1H NMR:
ı=5.95 (1H, dt, J=1.7, 0.8Hz), 3.99 (1H, d, J=10.6Hz), 3.89 (1H, d,
J=10.6Hz), 2.72–2.54 (3H, m), 2.46–2.34 (4H, m), 2.12–1.88 (5H,
m), 1.80 (1H, tdd, J=13.4, 5.1, 1.1Hz), 1.67–1.38 (6H, m), 1.35 (3H, d,
J=0.9Hz), 1.13 (1H, qd, J=12.4, 5.3Hz); 13C NMR: ı=199.23, 170.97,
165.30, 126,87, 82,61, 65, 81, 52.78, 46.21, 43.49, 39.52, 38.75, 34.77,
33.35, 33.17, 30.58, 28.52, 22.46, 20.17, 19.89.
4.2.8. 3,16˛-Dihydroxy 17a-oxa-17a-homo 1,3,5(10)-estratrien
17-one (12a)
Yield 20%. White powder; m.p. 248 ◦C; IR (nujol) 1715 cm−1;
ESI-MS: m/z 303 [M+H]+, 325 [M+Na]+; 1H NMR: ı=7.12 (1H, d,
J=8.6Hz), 7.16 (1H, s br), 6.64 (1H, dd, J=8.6, 2.8Hz), 6.57 (1H, d,
J=2.8Hz), 4.48 (1H, dd, J=10.4, 4.5Hz), 2.86–2.82 (2H, m), 2.48
(1H, dq, J=13.5, 3.7Hz), 2.41 (1H, td, J=11.0, 4.2Hz), 2.24–2.00
(3H, m), 1.88 (1H, td, J=13.8, 4.4Hz), 1.79 (1H, ddd, J=12.4, 11.0,
7.4Hz), 1.45–1.38 (1H, m), 1.39 (3H, s), 1.38–1.18 (4H, m); 13C NMR:
ı=175.14, 153.74, 137.71, 131.10, 126.51, 115,16, 113.10, 85.29, 64.62,
45.30, 42.45, 42.07, 39.40, 30.53, 29.72, 27.47, 26.04, 19.43.
4.2.9. 17ˇ-Hydroxy 4-oxa-4a-homo 5˛-androstan 3-one (14a)
Yield 24%.White powder;m.p. 240 ◦C; IR (nujol) 1732 cm−1; ESI-
MS:m/z307 [M+H]+, 329 [M+Na]+; 1HNMR:ı=4.28 (1H,dd, J=13.0,
8.9Hz), 3.69 (1H, dd, J=13.0, 1.2Hz), 3.63 (1H, t, J=8.6Hz), 3.62
(1H, s br), 2.69 (1H, ddd, J=14.5, 13.7, 1.8Hz), 2.50 (1H, ddd, J=14.5,
7.4, 1.5Hz), 2.10–2.01 (1H, m), 1.93 (1H, ddd, J=14.4, 7.6, 1.9Hz),
1.82 (1H, ddd, J=12.6, 4.2, 2.8Hz), 1.74 (1H, ddd, J=12.8, 4.1, 2.5Hz),
1.65–1.20 (11H, m), 1.06 (1H, td, J=12.8, 3.8Hz), 0.98–0.92 (1H, m),
0.94 (3H, s), 0.78–0.73 (1H, m), 0.74 (3H, s); 13C NMR: ı=176.03,
81.78, 70.02, 53.82, 50.93, 48.75, 42.83, 37.79, 36.66, 35.67, 35.08,
31.20, 30.58, 29.74, 26.29, 23.35, 20.76, 12.38, 11.12.
4.2.10. 17ˇ-Hydroxy 4-oxa-4a-homo 5ˇ-androstan 3-one (15a)
Yield 14%.White powder;m.p. 130 ◦C; IR (nujol) 1733 cm−1; ESI-
MS:m/z307 [M+H]+, 329 [M+Na]+; 1HNMR:ı=4.63 (1H,dd, J=13.0,
10.1Hz), 3.90 (1H,dd, J=13.0, 1.6Hz), 3.66 (1H, t, J=8.6Hz), 2.70 (1H,
ddd, J=14.7, 12.9, 1.3Hz), 2.38 (1H, ddd, J=14.7, 8.1, 1.1Hz), 2.11–1.84
(4H, m), 1.77 (1H, ddt, J=10.2, 5.0, 2.2Hz), 1.61–1.22 (11H, m), 1.13
(1H, td, J=12.6, 4.3Hz), 1.07–1.01 (1H, m), 1.04 (3H, s), 0,75 (3H,
d, J=0.6Hz), 0.75–0.77 (1H, m); 13C NMR: ı=176.00, 81.81, 70.40,
51.02, 45.59, 43.14, 41.77, 36.86, 36.73, 35.94, 33.39, 30.64, 28.35,
27.01, 26.89, 23.88, 23.37, 20.67, 11.12.
4.2.11. 4-Oxa-4a-homo 5˛-androstan 3,17-dione (16a)
Yield 30%.White powder;m.p. 233 ◦C; IR (nujol) 1733 cm−1; ESI-
MS:m/z305 [M+H]+, 327 [M+Na]+; 1HNMR: ı=4.29 (1H, dd, J=13.1,
9.0Hz), 3.71 (1H, dd, 13.1, 1.3Hz), 2.70 (1H, ddd, J=14.6, 13.2, 1.8Hz),
2.52 (1H, ddd, J=14.6, 7.4, 1.5Hz), 2.45 (1H, ddd, J=19.4, 9.1, 1.3Hz),
2.08 (1H, dt, J=19.4, 8.9Hz), 1.97–1.70 (5H, m) 1.61–1.23 (9H, m),
1.06 (1H, qd, J=13.2, 4.5Hz), 0.96 (3H, s), 0.86 (3H, s), 0.83 (1H,
ddd, J=11.8, 10.7, 4.1Hz); 13C NMR: ı=220.46, 175.84, 69.84, 53.72,
51.23, 48.64, 47.48, 37.83, 35.78, 35.53, 34.57, 31.45, 30.43, 29.65,
26.10, 21.71, 20.41, 13.78, 12.34.
4.2.12. 4,17a-Dioxa-4a,17a-dihomo 5˛-androstan 3,17-dione
(16b)
Yield 11%.White powder;m.p. 260 ◦C; IR (nujol) 1733 cm−1; ESI-
MS:m/z321 [M+H]+, 343 [M+Na]+; 1HNMR: ı=4.27 (1H,dd, J=13.2,
8.9Hz), 3.72 (1H, dd, J=13.2, 1.3Hz), 2.72–2.51 (4H, m), 2.00–1.91
(4H, m), 1.84 (1H, dq, J=13.8, 3.8Hz), 1.68–1.37 (7H, m), 1.30 (3H, d,
J=0.7Hz), 1.29–1.14 (2H, m), 1.07–0.96 (2H, m), 0.91 (3H, s); 13C
NMR: ı=175.66, 171.17, 82.76, 69.54, 52.35, 48.02, 46.08, 39.09,
37.67, 37.43, 35.30, 30.13, 29.54, 28.56, 25.99, 21.92, 20.08, 19.79,
12.24.
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